All eyes on CSX as Union Pacific and Norfolk Southern confirm talks
Speculation has pointed to Warren Buffett's Berkshire Hathaway (NYSE:BRKa), which owns BNSF, as a potential suitor. Additionally, one of the major Canadian railroads—either Canadian Pacific Kansas City Limited (NYSE:CP) or Canadian National Railway (NYSE:CNI) —could get involved. However, the Trump administration may oppose a cross-border deal involving a non-U.S. buyer.
Shares of CSX rose 0.5% in mid-day trading on Thursday, but are well off session highs.
CSX CEO Joseph Hinrichs addressed the rumors during the company's second-quarter earnings call on Wednesday evening. While stopping short of commenting on the speculation, he left the door open to opportunities that could create shareholder value.
'And finally, we know there's been a lot of rumor and speculation about consolidation in the railroad industry in recent weeks,' Hinrichs said in his opening remarks. 'While we cannot comment, we want to be clear that at CSX we are absolutely focused on delivering shareholder value and are always open to anything that can help us achieve this objective.'
Later in the call, JP Morgan analyst Brian Ossenbeck asked Hinrichs for his perspective on potential rail consolidation, noting his background as a former shipper.
Hinrichs, a 30-year auto industry veteran, emphasized that improving customer service and making it easier to do business with railroads is essential for industry growth. While again declining to comment on mergers, he stressed the importance of reliability, accessibility, and working across the rail ecosystem to better serve customers and compete with trucking.
'So again, I'm not going to talk about how we do that or all those, and as we said in our remarks, we're open to all those possibilities and all those conversations and how we could, we can do that, how we can best create value for our shareholders, properly grow the business and serve those customers better and look forward to those opportunities,' he added.
Related articles
All eyes on CSX as Union Pacific and Norfolk Southern confirm talks
These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia
If Powell goes, does Fed trust go with him?
擷取數據時發生錯誤
登入存取你的投資組合
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
擷取數據時發生錯誤
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. Multipotency refers to a flexible cellular state in which a cell has the potential to differentiate into multiple specialized cell types, depending on the environmental conditions or stimuli it encounters. While stem cells have garnered the most attention on being multipotent, fibroblasts are also considered multipotent and can be directly differentiated into many cell types including chondrocytes, osteocytes, hepatocytes and cardiomyocytes. This patent application broadly relates to methods for generating multipotent cells directly from fibroblasts found in human donor tissues. 'This method provides us with the ability to obtain larger quantities of stable and easily scalable multipotent cells from donor-derived fibroblasts for use in clinical applications,' said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. 'Multipotent fibroblasts also show enhanced ability to form 3D spheroid structures, further expanding their potential across a range of therapeutic and drug development areas.' Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, said, 'By enabling the generation of stable, multipotent cells directly from donor tissue, this innovation addresses long-standing challenges in the field and opens new possibilities for scalable, regenerative treatments.' For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of multipotent fibroblasts across a range of therapeutic and drug development areas and new possibilities for scalable, regenerative treatments. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347) in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Visa Q3 2025 Earnings Preview: Cross-Border Momentum vs. Cost Discipline
Visa (NYSE:V) reports third-quarter 2025 results after the bell on Tuesday, July 29. Shares closed at $357.04 on July 25, 2025, up 0.9% for the session and roughly 12% year-to-date, leaving the stock 5% shy of its June record high. Consensus points to EPS of $2.85 on $9.85 billion in revenue versus $2.42 on $8.9 billion a year ago, reflecting sustained payments-volume gains and cross-border tailwinds. Warning! GuruFocus has detected 7 Warning Signs with PARA. Investors will zero in on three main levers. First, cross-border volume, which rose 13% last quarter, a mid-teens print would confirm resilient travel spend even as airfare inflation eases. Second, expense control. Management guided mid-single-digit operating-expense growth, but elevated AI and tokenization spend could crimp margin expansion. Third, capital returns. Visa had $4.7 billion remaining in its buyback program, and the board has authorized another $30 billion. Any acceleration would influence EPS optics and free-cash-flow guidance. Watch for commentary on Visa+ P2P rollout, European interchange scrutiny, and competitive pressure from real-time-payments networks. With the share price near highs, even a routine beat may disappoint if cross-border growth cools or expense guidance creeps higher. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Is Twist Bioscience Corp. (TWST) Nearing Profitability?
Conestoga Capital Advisors, an asset management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter began with a historically poor start but gained momentum later as tariff fears subsided and market volatility dropped precipitously. Conestoga Micro Cap Composite appreciated 15.65% net-of-fees in the second quarter but underperformed the Russell Microcap Growth Index's 20.92% return. In a highly volatile market led by high-beta and lower-quality stocks, the firm does not expect the fund to align with index performance. Please review the fund's top 5 holdings to gain insight into their key selections for 2025. In its second quarter 2025 investor letter, Conestoga Capital Advisors highlighted stocks such as Twist Bioscience Corporation (NASDAQ:TWST). Twist Bioscience Corporation (NASDAQ:TWST) manufactures and distributes synthetic DNA-based products. The one-month return of Twist Bioscience Corporation (NASDAQ:TWST) was -2.17%, and its shares lost 37.34% of their value over the last 52 weeks. On July 25, 2025, Twist Bioscience Corporation (NASDAQ:TWST) stock closed at $35.99 per share, with a market capitalization of $2.16 billion. Conestoga Capital Advisors stated the following regarding Twist Bioscience Corporation (NASDAQ:TWST) in its second quarter 2025 investor letter: "Twist Bioscience Corporation (NASDAQ:TWST) is a rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform that manufactures synthetic DNA by 'writing' it on a silicon chip. TWST leverages their unique technology platform to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for NGS sample preparation, and antibody libraries for drug discovery and development. Conestoga was a shareholder of TWST from 2019 to 2020 and sold due to its market cap exceeding our limit. With the weakness in healthcare, Conestoga is reinvesting. TWST's fundamentals have remained robust, management has been upgraded, and we believe they are nearing profitability." A scientist holding a test tube in the lab, surrounded by equipment used in synthetic biology and drug discovery. Twist Bioscience Corporation (NASDAQ:TWST) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 30 hedge fund portfolios held Twist Bioscience Corporation (NASDAQ:TWST) at the end of the first quarter compared to 26 in the previous quarter. In the second quarter of 2025, Twist Bioscience Corporation (NASDAQ:TWST) reported revenue of $92.8 million, reflecting an increase of 23% year-over-year. While we acknowledge the potential of Twist Bioscience Corporation (NASDAQ:TWST) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Twist Bioscience Corporation (NASDAQ:TWST) and shared the list of best genomics stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.
